Precision Decisions in Metastatic Prostate Cancer: Key Clinical Summary Module 1
This is a summary of a presentation by Dr. Andrew Laccetti, MD, MS which you can find here. Before participating, please read our CME and disclosure information which can be found here.
This activity is supported by an independent medical educational grant from Pfizer. This online education program has been designed for for US Healthcare Professionals only.
HRR Biomarker Testing in Metastatic Prostate Cancer: Key Clinical Summary
Homologous recombination repair (HRR) biomarker testing is an increasingly important component of metastatic prostate cancer (mPC) management because identification of pathogenic HRR alterations can determine eligibility for PARP inhibitor–based therapies. Effective implementation requires testing early, using complementary germline and somatic approaches, and interpreting results within the clinical context.
Who should be tested?
- All patients with metastatic prostate cancer should undergo HRR testing, regardless of family history.
- Testing should encompass both germline and somatic alterations, including non-BRCA HRR genes.
- HRR testing should also be considered in patients with high-risk or very-high-risk disease and node-positive disease according to applicable guidelines and local practice.
- Testing should not be restricted to patients who have already developed castration-resistant disease. HRR status can inform treatment decisions throughout the metastatic disease pathway.
- MSI/MMR testing should be performed alongside HRR testing, as these biomarkers have separate therapeutic implications.
Germline and somatic testing are complementary
Germline testing identifies inherited variants present throughout the patient's cells and can:
- Identify hereditary cancer predisposition.
- Inform treatment eligibility where germline alterations are clinically relevant.
- Have implications for family members and cascade testing.
Somatic testing evaluates tumour-derived alterations and can:
- Identify acquired HRR alterations that may not be present in the germline.
- Capture tumour-specific genomic changes relevant to targeted treatment.
- Be performed using tumour tissue or circulating tumour DNA (ctDNA), depending on the clinical setting and available sample.
Using only one approach can therefore miss clinically relevant information. When feasible, germline and somatic testing should be viewed as complementary rather than interchangeable.
When should testing occur?
Testing should be incorporated early in the metastatic pathway, ideally when metastatic disease is confirmed and before treatment decisions that could depend on biomarker status.
A practical workflow is:
- Confirm metastatic disease.
- Initiate germline and somatic HRR testing promptly.
- Use the diagnostic prostate biopsy or another suitable tumour specimen for somatic testing when appropriate.
- Obtain germline testing through an established blood or saliva-based pathway.
- Review results before subsequent treatment decisions and revisit genomic findings as the disease evolves and treatment options change.
Early testing helps prevent patients reaching later treatment lines without a known biomarker status and reduces the risk that declining clinical condition or inadequate tissue will prevent testing.
Choosing the testing modality
Tumour tissue
- An available, adequate diagnostic tissue block is generally a strong starting point for somatic testing.
- Prostate biopsy material may provide useful tumour DNA without requiring another invasive procedure.
- Older, scant or decalcified specimens may provide inadequate DNA quality.
- Where bone tissue is being considered, non-decalcified material should be requested whenever possible, because decalcification can degrade DNA.
ctDNA
- ctDNA can provide a practical alternative when suitable tissue is unavailable or inadequate.
- It can capture clinically relevant alterations present in metastatic disease without requiring a new tissue biopsy.
- However, low tumour fraction can substantially reduce sensitivity.
- A negative ctDNA result in a patient with low tumour fraction should therefore not automatically be interpreted as absence of an HRR alteration; tissue confirmation should be considered when clinically appropriate.
Interpreting the genomic report
Not every reported HRR alteration should automatically trigger targeted treatment.
Pathogenic or actionable alteration
- Confirm that the alteration is classified as pathogenic or otherwise clinically actionable.
- Determine whether the specific alteration is relevant to the intended PARP inhibitor regimen.
- Check the disease setting and applicable treatment indication, as eligibility can vary by regimen and clinical context.
Non-actionable or uncertain alteration
- Do not treat solely on the basis of an alteration that lacks sufficient evidence for clinical action.
- Do not disregard the patient permanently; variant classifications and treatment evidence can evolve, so relevant findings should be periodically re-reviewed.
Low-variant allele frequency alterations
- Low-level variants, particularly in genes such as ATM or CHEK2, require careful interpretation.
- Consider whether the finding could represent clonal hematopoiesis rather than a tumour-derived alteration.
- Confirm potentially actionable findings using tumour tissue or paired testing before making a treatment decision when appropriate.
Suspected germline finding
- A somatic result suggesting possible germline origin should prompt confirmatory germline testing.
- Where an inherited pathogenic variant is confirmed, appropriate genetic counselling and consideration of cascade testing should follow.
Building a real-world testing workflow
Successful implementation is not only about selecting the right assay; it also requires clear ownership of each step.
A standardized pathway should:
- Establish a default owner responsible for initiating testing when metastatic disease is confirmed.
- Use reflex or pre-defined testing pathways where possible rather than relying on individual clinicians to remember each step.
- Establish clear processes for obtaining and processing tissue.
- Use ctDNA when tissue is unavailable, inadequate or unsuitable, while recognizing its limitations.
- Define who reviews genomic reports and communicates actionable findings.
- Ensure suspected germline findings are referred for appropriate confirmation.
- Revisit previously negative or non-actionable findings when testing technology, variant classification or treatment evidence changes.
Clinical takeaway
HRR testing should be an early, standardized part of metastatic prostate cancer care—not a test reserved for mCRPC after treatment options have narrowed. Both germline and somatic testing are important because they identify different types of alterations. Results should be interpreted according to the specific gene, pathogenicity, variant allele frequency, potential germline origin, disease setting and treatment indication. A coordinated workflow that combines early testing, appropriate sample selection and expert genomic interpretation can help ensure that patients with actionable HRR alterations, including non-BRCA mutations, are identified in time to inform targeted treatment decisions.
Content is accurate as of the date of release.